ObjectiveTo explore the clinical efficacy of sacubitril-valsartan in patients with hypertension. MethodsA total of 90 patients with hypertension were selected and randomly divided into two groups: the control group (n=45) was treated with nifedipine controlled-release tablets alone, and the study group (n=45) was treated with sacubitril-valsartan, both groups were treated for 4 weeks. The clinical efficacy, as well as the ambulatory blood pressure, plasma anticoagulant indexes levels, plasma inflammatory factors levels, and vascular endothelial function indexes levels before and after the treatment, and post-treatment incidence of adverse reactions were compared between the two groups. ResultsAfter 4 weeks of treatment, as compared with the control group, the study group had better clinical efficacy, lower 24h mean diastolic blood pressure (85.60 ± 3.56 mmHg vs. 90.22 ± 3.13 mmHg), lower plasma platelet α-granule membrane protein 140, plasminogen activator inhibitor, tumor necrosis factor-α, interleukin-6, C-reactive protein, and endothelin levels, and higher plasma tissue-type plasminogen activator, and nitric oxide levels (all P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment (P＞0.05). ConclusionIn the treatment of patients with hypertension, sacubitril-valsartan can effectively reduce their diastolic blood pressure, improve blood viscosity, inflammatory response, and vascular endothelial function, with a high safety value.

无